News

AliveDx and Global Marketing Services (GMS) have signed distribution agreements, which will enable Global Marketing Services to distribute MosaiQ® and Alba products in Pakistan. The distribution agreements take effect immediately. This strategic partnership acts as a reminder of AliveDx’s commitment to growing and expanding its geographical reach. It will enable both parties to improve patient…

We are excited to announce that our abstract titled “Performance of a Novel, Fully-automated Multiplexed Immunoassay Microarray Prototype for Serological Detection of Eleven Autoantibodies Found in Connective Tissue Diseases” will be presented at the 25th Asia-Pacific League of Associations for Rheumatology Congress (APLAR 2023) in Chiang Mai, Thailand. Join us on Saturday, 9 December 2023,…

AliveDx and Bio-Strategy have signed distribution agreements, which will enable Bio-Strategy to distribute MosaiQ® products in Australia, New Zealand, and the Pacific Islands, and Alba products in New Zealand. The distribution agreements take effect immediately. This strategic partnership serves as a reminder of AliveDx’s unwavering dedication to developing and broadening its geographical presence. It will…

We are delighted to unveil The L.I.V.E. Xchange, our new showroom and innovation space, at our headquarters in Eysins, Switzerland. The L.I.V.E. Xchange was created to give our customers, development partners, distributors, and other stakeholders access to a dynamic environment that encourages collaboration and creativity by allowing ideas and innovation to flow freely. The new…

AliveDx and Rowad Medical Services have signed a distribution agreement, which will enable Rowad Medical Services to distribute AliveDx’s products, Alba and MosaiQ®, in the Kingdom of Saudi Arabia. The distribution agreement takes effect immediately. This strategic partnership reaffirms AliveDx’s consistent commitment to grow and expand its geographical presence. It will enable both parties to…

Last week, AliveDx held its first Golden Partners Meeting at its headquarters in Eysins, Switzerland. For four consecutive days, our Golden Partners from all around the world engaged with our management team and representatives from our commercial, regulatory, and technical teams. Our Golden Partners attended presentations, brainstorming sessions, and visited our manufacturing facilities. They also…

We are excited to announce that our abstract on the microarray prototype for the serological detection of eleven IgG autoantibodies commonly found in Connective Tissue Diseases was presented at ACR Convergence 2023, held in San Diego, California. Our poster titled “Performance Characteristics of a Novel, Fully Automated Multiplexed Immunoassay Microarray Prototype forthe Serological Detectionof Eleven…

AliveDx receives three IVDR CE Marks for its automated, multiplexed MosaiQ® solution, enabling faster diagnosis of Connective Tissue Diseases (CTD). Eysins, 24 October 2023 — AliveDx is proud to announce it has received three CE Marks for: Its MosaiQ Centromere Protein B (CENP-B) microarray,its MosaiQ AiPlex CTD (Connective Tissue Diseases) multiplexed microarray immunoassays and its…

We are thrilled to announce a transformative milestone in our journey—a comprehensive rebranding effort aimed at better reflecting the company’s mission, values, and vision for the future.

We recently announced that the new ALBA Elution Kit was CE marked. We are delighted to say it is now also FDA registered! The ALBA Elution Kit for the acid elution of antibodies from intact red cells produces 10 elutions per kit, delivers a distinct pH change reaction, offers room temperature storage, user-friendly instructions, and…